Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

M&A and IPOs

September 6, 2013: 10:07 AM ET

Amobee, a digital advertising company owned by SingTel, has acquired Gradient X, a Santa Monica, Calif.–based real-time bidding platform. No financial terms were disclosed. Gradient X has raised around $4 million in VC funding from Rincon Venture Partners, GRP Partners, Crosscut Ventures, Siemer Ventures, Founder Collective, Baroda Ventures and individual angels. www.gradientx.com

Bunge Ltd. (NYSE: BG) has agreed to sell its 50% stake in its Moroccan fertilizer joint venture (Bunge Maroc Phosphore) to JV partner OCP Group. No financial terms were disclosed.www.ocpgroup.ma

Suntory Beverage & Food Ltd. (Tokyo: 2587) is in "advanced talks" to buy the Lucozade andRibena beverage brands of GlaxoSmithKline (LSE: GSK) for more than 1 billion, according to Reuters. An agreement could be announced within the next several days. www.suntory.com

Braintree, a Chicago-based payment platform for online and mobile commerce, is shopping itself to potential acquirors with a $1 billion asking price, according to TechCrunch. So far it has held discussions with such companies as PayPal and Square. Braintree has raised $70 million in VC funding from firms like Accel Partners and New Enterprise Associates. www.braintreepayments.com

Acceleron Pharma Inc., a Cambridge, Mass.-based developer of protein therapeutics for cancer and rare diseases, has set its IPO terms to 4.65 million shares being offered at between $13 and $15 per share. It would have an initial market cap of approximately $360 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol XLRN, with Citigroup and Leerink Swann serving as co-lead underwriters. Shareholders include Polaris Venture Partners (15.6% pre-IPO stake), Venrock Partners (12.4%), Advanced Technology Ventures (12.5%), Celgene Corp. (12.3%), Flagship Ventures (11.1%), OrbiMed Advisors (10.6%), Bessemer Venture Partners, Alkermes, Avalon Ventures and Sutter Hill Ventures. www.acceleronpharma.com

BenefitFocus Inc., a Charleston, S.C.-based provider of cloud-based benefits software for consumers, employers and brokers, has set its IPO terms to 4.5 million shares being offered at between $21.50 and $24.50 per share. It would have an initial market cap of approximately $559 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol BNFT, with GoldmanSachs, Deutsche Bank and Jefferies serving as lead underwriters. Shareholders include Goldman Sachs (65.95% pre-IPO stake) and Oak Investment Partners (11.45%).www.benefitfocus.com

Bind Therapeutics Inc., a Cambridge, Mass.-based nanomedicines company, has set its IPO terms to 4.7 million shares being offered at between $14 and $16 per share. It would have an initial market cap of approximately $237 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol BIND, with Credit Suisse and Cowen & Co. serving as lead underwriters. Shareholders include Polaris Venture Partners (18% pre-IPO stake), Flagship Ventures (13.9%), Rusano (11.5%), DHK Investments (8.6%), Arch Venture Partners (8.5%) and NanoDimension (6%). www.bindtherapeutics.com

Sign up for Dan's daily email newsletter on deals and deal-makers: GetTermSheet.com

Posted in: ,
Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.